Skip to main content

Table 3 Clinical characteristics of psychiatric patients stratified by achieving SVR-12

From: Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders

 SVR-12 (N = 127)No SVR-12 (N = 17)p-value
Sex, males.n(%)58 (45.7%)13 (76.5%)0.020
Age, years, mean (SD)61.8 ± 13.351.6 ± 11.70.038
Risk Factorsn(%)
IDU28 (22.0%)9 (52.9%)0.014
Heterosexual10 (7.9%)00.607
MSM1 (0.8%)01.000
 Nosocomial36 (28.3%)2 (11.8%)0.239
Unknown52 (41.0%)6 (35.3%)0.794
HCV Genotypesn(%)
1a27 (21.3%)5 (29.4%)0.534
1b45 (35.4%)6 (35.3%)1.000
235 (27.6%)2 (11.8%)0.238
315 (11.8%)3 (17.6%)0.448
45 (3.9%)1 (5.9%)0.536
Log 10 HCV-RNA, IU/mL, median (range)6.00 (5.5–6.5)6.1 (5.5–6.7)0.841
Liver stiffness, Kpa, mean (SD)11.1 ± 10.48.9 ± 3.4 
Previous failure,n(%)24 (18.9%)8 (47.0%)0.024
INF-based tx238 
DAAs-based tx10 
FIB-4 score median (range)2.0 (1.4–3.3)1.5 (1.3–2.1)0.226
APRI score median (range)0.6 (0.4–1.2)0.6 (0.5–1.2)0.936
MELD score median (range)7.0 (6.0–8.0)7.0 (6.0–7.0)0.794
Cirrhosis,n(%)40 (31.5%)6 (35.3%)0.785
Oesophageal varices or portal hypertension,n(%)13 (10.2%)2 (11.8%)0.691
Type of HCV therapyn(%)
 SOF + RBV7 (5.5%)00.594
 SOF + SMV ± RBV5 (3.9%)01.000
 SOF + LDV ± RBV18 (14.2%)3 (17.6%)0.715
 SOF + DCV ± RBV11 (8.7%)2 (11.8%)0.652
 OMB + PTV/r + DAS ± RBV13 (10.2%)2 (11.8%)0.691
 OMB + PTV/r + RBV1 (0.8%)1 (5.9%)0.222
 SOF + VEL ± RBV30 (23.6%)7 (41.2%)0.141
 GLE + PIB24 (18.9%)00.076
 GRZ + EBR ± RBV18 (14.2%)2 (11.8%)1.000
Addition of RBVn(%)27 (21.2%)6 (35.3%)0.222
ALT, UI/L, median (range)50 (28.5–77.5)70 (47–125)0.031
Total bilirubin, mg/dL, median (range)0.62 (0.44–0.83)0.60 (0.40–0.80)0.561
Serum creatinine, mg/dL, median (range)0.79 (0.61–0.95)0.78 (0.63–0.80)0.928
Platelets (×10^9/L), median (range)182 (139–219)185 (157–210)0.920
Patients with at least 1 other comorbidity, n (%)94 (74%)7 (41.2%)0.009
Diabetes,n(%)18 (14.2%)2 (11.8%)1.000
Hypertension,n(%)57 (44.9%)4 (23.5%)0.119
HIV infected,n(%)17 (13.4%)2 (11.8%)1.000
  1. Legend: IDU Injecting drug user, MSM Man who have sex with man, INF Interferon, DAA Direct antiviral agent, SOF Sofosbuvir, RBV Ribavirin, SMV Simeprevir, LDV Ledipasvir, DCV Daclatasvir, OMB Ombitasvir, PTV/r Paripatrevir/ritonavir, DSV Dasabuvir, VEL Velpatasvir, GLE Glecaprevir, PIB Pibrentasvir, GRZ Grazoprevir, EBR Elbasvir, ALT Alanine aminotransferase, ART Antiretroviral therapy